Keloid Clinical Trials 2023

What are the top hospitals conducting keloid research?

Keloid, a challenging and often misunderstood condition characterized by the formation of excessive scar tissue, is being actively investigated in some of the top hospitals across the United States. In New york City, the Icahn School of Medicine at Mount Sinai takes on this complex issue with two ongoing keloid trials. Although their overall contribution to keloid research is relatively recent, having recorded their first trial in 2021, they are committed to unraveling the mysteries that surround this condition. Meanwhile, Yale New Haven Hospital in Connecticut stands as another key player in the pursuit of knowledge about keloids. With one active trial and a history-making debut just last year in 2022, they have already made significant strides towards understanding this perplexing condition.

Not far behind lies the University of California San Diego where researchers also delve into finding effective approaches for managing keloids. This esteemed institution currently engages in one active clinical trial while sharing a similar timeline with Yale New Haven Hospital since recording their first-ever keloid investigation also occurred recently making it solely last year- thus outlining significant momentum within such short span further fueling hope among patients diagnosed with Keloids.

Additionally contributing to these efforts is Beth Israel Deaconess Medical Center located in Boston who has joined other leading healthcare providers by investing time and resources into combating these stubborn scars through an active clinical test; mirroring others' achievements there too debuted only earlier three years later from current point until now i.e.,starting 2023.The Albert Einstein College of Medicine situated amidst Bronx neighborhood completes our list but certainly not without significance.Though conducting single ongoing trail at present like others however serving rays optimism by embarking journey earliest out all five participants as backfence dates back upto 2020 marking them front runner steed initiating path toward understandings & interventions against Keloids

The collective dedication exhibited by these hospitals underscores not only their commitment to tackling keloids but reflects a broader commitment within medical community towards improving the quality of life for individuals living with this challenging condition. Through their innovative trials and tireless efforts, they pave the way towards a future where keloid management is more effective, providing hope for those affected by these burdensome scars.

Which are the best cities for keloid clinical trials?

In the realm of keloid clinical trials, several cities emerge as leading hubs for research and development. New york, New York offers two active trials focusing on treatments like Duobrii and Dupilumab. The Bronx in New York also presents two ongoing trials centered around radiation therapy for unresected keloids. In New Haven, Connecticut, there is one active trial exploring preoperative silicone ointment among other approaches. San Diego, California contributes to the field with a notable trial investigating Botulinum toxin type A. Lastly, Boston, Massachusetts hosts one active study examining Dupilumab's effects. These cities collectively serve as key centers where individuals seeking participation in keloid clinical trials can find opportunities to contribute towards advancements in treatment options for this condition.

Which are the top treatments for keloid being explored in clinical trials?

Exciting developments are taking place in the field of keloid treatment, as evidenced by ongoing clinical trials exploring various approaches. Among the top treatments being investigated are:

• Dupilumab: This promising drug is currently undergoing two active trials for keloids. It was first listed in 2021 and has shown potential in managing this challenging condition.

• Preoperative silicone ointment: A novel approach, preoperative silicone ointment is being tested in one active trial for keloids. Its first listing occurred in 2022, and early results indicate it may hold promise as a treatment option.

• Botulinum toxin type A: Another intriguing possibility lies with botulinum toxin type A, which is currently under investigation through one active trial specifically targeting keloids. Introduced to research in 2022, its potential benefits offer hope for patients seeking effective therapies.

• Radiation therapy of unresected keloids: An alternative path being explored involves radiation therapy applied to unresected (not surgically removed) keloids. With one active trial dedicated to this method and initial listing dating back to 2020, researchers aim to determine its effectiveness against this persistent condition.

As these clinical trials progress and more data becomes available, we move closer towards identifying improved strategies for treating keloids effectively.

What are the most recent clinical trials for keloid?

Recent clinical trials offer new hope for individuals dealing with keloid, a condition characterized by the formation of raised scars. Among these trials is the investigation of dupilumab, a potential treatment that has shown promise in reducing keloid growth. Additionally, another trial focuses on duobrii and its efficacy in managing keloids. These studies contribute to advancing our understanding of effective interventions for this challenging condition. With ongoing research efforts like STP705 also exploring potential treatments, there is renewed optimism for those seeking relief from keloids' burdensome impact on their quality of life.

What keloid clinical trials were recently completed?

Recently, two clinical trials focusing on keloid treatments have successfully concluded. In June 2021, AiViva BioPharma completed their trial for AIV001, offering potential advancements in the management of keloids. Additionally, NYU Langone Health wrapped up a study in January 2021 that examined the effectiveness of Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil as a treatment option. These recent developments signify promising progress in tackling keloid-related challenges and provide hope for individuals seeking effective therapies against this condition.